

Mouse Fumarate Hydratase/Fumarase Monoclonal Antibody

Fumarate Hydratase/Fumarase (BSB-151)

CATALOG # AAA59370	HOST Mouse	REACTIVITY Human, Mouse, Rat
------------------------------	----------------------	--


PRODUCT SYNONYMS

Fumarate Hydratase/Fumarase; Monoclonal Antibody; Fumarate Hydratase/Fumarase (BSB-151); fumarate hydratase; fumurase; anti-fumurate hydratase; anti-fumurase; fh; anti-fh; fumurate; fumarate; fumerate; FH; Fh1; FMRD; HLRCC; LRCC; MCL; MCUL1; Fumarate hydratase mitochondrial; anti-Fumarate Hydratase/Fumarase antibody

PRODUCT SPECIFICATIONS

Host	Mouse
Reactivity	Human, Mouse, Rat
Clonality	Monoclonal
Isotype	IgG1
Clone Number	BSB-151
Form/Format	Paraffin, Frozen Anti-fumarate hydratase is a mouse monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH7.5, containing BSA and sodium azide as a preservative.
Immunogen	Synthetic peptide corresponding to the C-terminus of the human fumarate hydratase protein.
Control	Placenta, Breast, Fallopian Tube, Colon, Kidney, Testis, Colon Adenocarcinoma, HER2 Negative Breast Cancer
Localization	Cytoplasmic
Preparation and Storage	Store at 2-8 degree C (Control Slides: Store at 20-25 degree C)

IMAGES



IHC (Immunohiostchemistry)

Antibody Type	Dilution	Volume/Qty
Prediluted	Ready-To-Use	3.0 ml
Prediluted	Ready-To-Use	7.0 ml
Prediluted	Ready-To-Use	15.0 ml
Concentrated	1:25-1:100	0.1 ml
Concentrated	1:25-1:100	0.5 ml
Concentrated	1:25-1:100	1.0 ml
Control Slides		5

Dilution Info

ADDITIONAL INFORMATION

Related Product Information for anti-Fumarate Hydratase/Fumarase antibody	Fumarate hydratase (FH), or fumarase, is encoded by the FH gene, which is an enzymatic component of the tricarboxylic acid (TCA) cycle, or Krebs cycle, where it catalyzes the formation of L-malate from fumarate. Mutations in the FH gene can cause FH deficiency and lead to progressive encephalopathy. It was discovered that succinate dehydrogenase and FH are tumour suppressors and they are associated with metabolic dysfunction and tumorigenesis, providing biochemical evidence to explain enhanced glycolysis in tumours. Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is an autosomal dominant heritable syndrome with predisposition to development of Renal Cell Carcinoma and Smooth Muscle Tumors of the skin and uterus. Cells of individuals with HLRCC had lower fumarate hydratase antibody activity than cells from normal controls, making fumarate hydratase antibody activity testing a useful method for identification and screening. Loss-of-function mutations of FH predisposes individuals to the autosomal dominant syndrome of Multiple Cutaneous and Uterine Leiomyomatosis (MCUL). Biallelic inactivation/mutations of FH are seen in 85% of Hereditary Leiomyomatosis and Renal Cell Carcinoma cases, 100% of Renal Cell Carcinoma with germline FH mutations, 19% of Papillary Renal Cell Carcinoma (Type II) have FH deficiency and 90% of FH deficiency RCC have FH mutations, 1% of unselected Leiomyomas, 2.6% of Leiomyomas in patients < 40 years old and 37- 52% of Leiomyoma with bizarre nuclei.
---	--

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://stage.aaabiotech.com/monoclonal/fumarate-hydratase-fumarase-antibody-clone-bsb-151-elisa/59370>